ArticleBiomedical engineering online2026
OxyJet CPAP: an electricity-free low-cost emergency respiratory support device.
Article in Biomedical engineering online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory support devices in resource-limited settings should be inexpensive, portable, effective, and easy to use. Non-invasive respiratory support devices can reduce expensive ICU admissions, but these facilities are severely lacking in low-resource settings. Here, we describe the design and validation of a low-cost, portable, electricity-free, and 3D-printed continuous positive airway pressure (CPAP) device named 'OxyJet' that can provide non-invasive respiratory support outside the ICU. The OxyJet is uniquely built using off-the-shelf components and 3D printing technology, making it both inexpensive and easy to produce. OxyJet costs less than 10% of the price of a similar CPAP system. Inspired by the fundamental mechanics of gas ejectors and harnessing the potential energy of a high-pressure oxygen jet, the device can deliver a high flow of oxygenated air up to 65 L/min (approx.), a positive end-expiratory pressure (PEEP) within 5-15 cmH
resultsThe device was bench-tested following UK-MHRA RMCPAP guidelines and tested on healthy volunteers (n = 5) and hypoxemic patients (n = 5). A comparative pilot study involving 23 hypoxemic adult patients conducted in Dhaka, Bangladesh, showed a significant improvement (p < 0.05) in the peripheral oxygen saturation (SpO
conclusionOur findings suggest that OxyJet CPAP has the potential to serve as an emergency respiratory support device outside the ICU, strengthening health systems in resource-limited settings.
methodsOxyJet's performance was first assessed through benchtop testing following the UK-MHRA RMCPAP protocol. This was followed by preliminary human testing in healthy volunteers and hypoxemic patients to evaluate safety and usability. A pilot feasibility study involving hypoxemic adult patients in Dhaka, Bangladesh, was then conducted to compare the device's physiological effects with those of standard CPAP therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.